Bli medlem
Bli medlem

Du är här

2020-09-10

ExpreS2ion Biotechnologies: ExpreS2ion will present its technology platform and pipeline at several key events in September and October 2020

During these and additional scientific and business partnering meetings, ExpreS[2]ion will present the advantages of the ExpreS[2] protein production and capsid virus-like particle (cVLP) technology platforms for vaccine discovery, preclinical development and good manufacturing practice (GMP) production for clinical studies, with a special focus on its COVID-19 vaccine project in collaboration with its joint venture AdaptVac.

CEO Bent Frandsen comments

"Our ExpreS[2] platform is a leading tool for rapid development and GMP production of advanced and hard-to-express vaccines, as shown by its use in several high-profile malaria projects and the PREVENT-nCoV COVID-19 vaccine development program. With an ambitious clinical program for the COVID-19 vaccine planned for 2021, and the recent announcement that we intend to in-license the promising AV001 breast cancer vaccine candidate from our joint venture AdaptVac, we are now executing on our plan to take ExpreS[2]ion to the next level with an in-house pipeline of vaccine development projects. At these events, we hope to meet potential collaboration partners as well as presenting our company to shareholders and other stakeholders. I am excited to lead ExpreS[2]ion and our continued work to create world-class treatments for some of the most important medical challenges of our time."

ExpreS[2]ion will participate in the following event activities in September and October, 2020:

Aktiespararna's Aktiedagen, September 15, Lund, Sweden

See the company presentation by our CEO, Bent U. Frandsen, at this investor event, which is digital and broadcasted live. Make a participant reservation at Aktiespararna's website (https://www.aktiespararna.se/aktiviteter/aktiedagen-digitalt-15-september).

World Vaccine Congress Washington Virtual, September 28-October 1
To learn more about ExpreS[2] and the unique VLP technology, see Dr. Max Soegaard, VP R&D, present our proof-of-concept in animals-stage COVID-19 vaccine project. Pre-arrange meetings via email on info@expreS2ionbio.com.More information at WVC's website (https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm).

Webinar on Denmark's response to COVID-19, September 29, Japan
ExpreS[2]ion and its joint venture AdaptVac's involvement in the PREVENT-nCoV COVID-19 vaccine program is presented by CEO Bent U. Frandsen at this webinar aimed at a Japanese audience. The event highlights Denmark's efforts in response to the COVID-19 pandemic. It is co-hosted by the Danish public-private partnership organization Healthcare Denmark and the Royal Danish Embassy, Tokyo. Registration and more information about the event via the following links:

Registration in English (https://japan.um.dk/~/media/japan/documents/covid-19%20life%20science%20webinar%20annoncement.pdf?la=en)

Registration in Japanese (https://japan.um.dk/~/media/japan/covid-19%20webinar%20jp%20final.pdf?la=ja)

World Vaccine Congress Europe Digital Event, October 19-21
To learn more about ExpreS[2] and the unique VLP technology, see Dr. Max Soegaard, VP R&D, present our proof-of-concept in animals-stage COVID-19 vaccine project. Pre-arrange meetings via email on info@expreS2ionbio.com.More information at WVC Europe's website (https://www.terrapinn.com/conference/world-vaccine-congress-europe/index.stm).

Life Science Investor Conference by Økonomisk Ugebrev, October 21, Denmark
See the company presentation by our CEO, Bent U. Frandsen, at this investor event. The presentation will be held in Danish. More information at the webpage of the event (https://www.eventbrite.co.uk/e/life-science-investor-konferencer-21oktober-2020-tickets-119875190923).

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se
 

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.